Securities Litigation Arising from Alzheimer's Drug Treatments

The legal challenges surrounding Biogen’s Aduhelm and Cassava Sciences’ simufilam underscore the ongoing difficulties in Alzheimer’s drug development, leading to securities litigation over allegedly misleading statements about trial results and commercialization efforts.